

Medical Policy Update

We regularly develop and revise medical policies in response to changing medical technology. Benefit determinations are made based on the medical policy in effect at the time of the provision of services. Please view the following updated and new medical policies, all of which can be found on our Provider page at www.lablue.com/providers, under "Medical Management," click "Medical Policies."

Updated Medical Policies

Policy No. Policy Name

Effective June 1, 2026

- 00014 Chelation Therapy
- 00134 Vagus Nerve Stimulation
- 00472 Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors [alirocumab (Praluent®), evolocumab (Repatha™)]
- 00522 prednisone delayed release tablets (Rayos®, generics)
- 00641 Pharmacotherapy for Gaucher Disease
- 00743 berotralstat (Orladeyo™)
- 00768 pegcetacoplan (Empaveli™)
- 00805 Select Vascular Endothelial Growth Factor (VEGF) Inhibitors and Combination Products
- 00839 Accrufer® (ferric maltol)
- 00876 iptacopan (Fabhalta®)
- 00928 vanzacaftor/tezacaftor/deutivacaftor (Alyftrek™)
- 00757 Adjunctive Techniques for Screening and Surveillance of Barrett Esophagus and Esophageal Dysplasia

Effective July 1, 2026

- 00255 Metformin and Metformin Containing Products
- 00280 Viscocanalostomy and Canaloplasty
- 00415 Tibial Nerve Stimulation
- 00426 Microprocessor-controlled Prostheses for the Lower Limb
- 00455 Treatment of Hepatitis C with sofosbuvir/ledipasvir (Harvoni®, Authorized Generic)
- 00518 Select Muscle Relaxants
- 00552 Eucrisa™ (crisaborole)
- 00567 dupilumab (Dupixent®)
- 00646 Calcitonin Gene-related Peptide (CGRP) Antagonists
- 00776 Pharmacotherapy for Presbyopia
- 00798 budesonide delayed release (Tarpeyo™)
- 00840 trofinetide (Daybue®, Daybue® Stix)
- 00886 Wegovy™ (semaglutide)

Effective Aug. 1, 2026

- 00003 Analysis of Human DNA or RNA in Stool Samples as a Technique for Colorectal Cancer Screening
- 00011 Bone Growth Stimulation
- 00077 Percutaneous Intradiscal Electrothermal Annuloplasty, Radiofrequency Annuloplasty, Biacuplasty and Intraosseous Basivertebral Nerve Ablation
- 00023 Cryoablation of Tumors Located in the Kidney, Lung, Breast, Pancreas or Bone
- 00106 Prolotherapy
- 00260 Spinal Cord and Nerve Root Stimulators
- 00296 Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
- 00395 Insulins (Non-long Acting Products)
- 00549 Intravitreal and Suprachoroidal Corticosteroid Products
- 00550 Treatment for Spinal Muscular Atrophy
- 00605 Chimeric Antigen Receptor T-cell (CAR-T) Therapy
- 00754 Monoclonal Antibodies for the Treatment of Alzheimer's Disease

New Medical Policies

Policy No. Policy Name

Effective June 1, 2026

- 00965 Tonmya™ (cyclobenzaprine sublingual tablet)
- 00966 garadacimab (Andembry®)
- 00967 sebetralstat (Ekterly®)
- 00968 donidalorsen (Dawnzera™)
- 00969 Cardamyst™ (etripamil)
- 00971 aficamten (Myqorzo™)

Effective July 1, 2026

- 00972 sibeprenlimab (Voyxact®)
- 00973 tividenofusp alfa-eknm (Avlayah™)
- 00974 Pivya™ (pivmecillinam)

Effective Aug. 1, 2026

- 00961 Surgical Treatment of Tarlov Cyst
- 00975 Immersive Virtual Reality Therapy for Chronic Lower Back Pain
- 00979 zopapogene imadenovec (Papzimeos™)